In addition, the identification of the Dnmt1 as a crucial actor of the methylation of the caspase1, caspase4 and DR5 genes suggests that the use of Dnmt1 inhibitor such as the MG-98 (a second-generation Dnmt1-specific anti-sense inhibitor currently in phase II clinical trials) or the SGI-1027 could be used to promote or restore the sensitivity of apoptosis induced by the TNF or TRAIL systems in glioma [27,28]. This evidence concerns the gene TNFSF10 and central nervous system cancer.